Early indication of survival benefit from ERCC1 and RRM1 tailored chemotherapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC). Evidence from an individual patient analysis

BACKGROUND: ERCC1 and RRM1 are molecular determinants that predict sensitivity or resistance to platinum agents and gemcitabine, respectively. Tailored therapy using these molecular determinants suggests patient benefit in a previously reported phase II trial. Here we report an individual patient an...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Simon, George R., Schell, Michael J., Begum, Mubeena, Kim, Jongphil, Chiappori, Alberto, Haura, Eric, Antonia, Scott, Bepler, Gerold
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3270127/
https://ncbi.nlm.nih.gov/pubmed/22028294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26522
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky